Mereo BioPharma (MREO) Common Equity (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Common Equity of $34.1 million for Q1 2026, down 43.32% year-over-year from $60.1 million in Q1 2025, and down 16.77% quarter-over-quarter from $40.9 million in Q4 2025.
Mereo BioPharma (MREO) Common Equity (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Common Equity for 10 consecutive years, with $34.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 43.32% year-over-year to $34.1 million; the TTM figure through Mar 2026 stood at $34.1 million (down 43.32% YoY), while the FY2025 annual figure was $40.9 million, down 32.89% from the prior year.
- Common Equity slipped to $34.1 million in Q1 2026 per MREO's latest filing, from $40.9 million in the prior quarter.
- Across five years, Common Equity topped out at $87.6 million in Q2 2022 and bottomed at -$72.5 million in Q3 2024.
- Historically, Common Equity has averaged $47.0 million across 5 years, with a median of $50.5 million in 2023.
- Annual changes were most pronounced in 2024 — Common Equity tumbled 232.59% — and 2025, when it surged 164.24%.
- Mereo BioPharma's Common Equity stood at $72.6 million in 2022, then plunged by 30.36% to $50.5 million in 2023, then grew by 20.64% to $61.0 million in 2024, then sank by 32.89% to $40.9 million in 2025, then declined by 16.77% to $34.1 million in 2026.
- Business Quant data shows MREO's Common Equity at $34.1 million in Q1 2026, $40.9 million in Q4 2025, and $46.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 9.79 Bn |
| 10 | Mereo BioPharma | 47.43 Mn | 47.43 Mn | - | 28.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.65 Mn |
| Mar 31, 2026 | 34.05 Mn |
| Dec 31, 2025 | 40.92 Mn |
| Sep 30, 2025 | 46.60 Mn |
| Jun 30, 2025 | 54.18 Mn |
| Mar 31, 2025 | 60.08 Mn |
| Dec 31, 2024 | 60.97 Mn |
| Sep 30, 2024 | -72.54 Mn |
| Jun 30, 2024 | 78.65 Mn |
| Mar 31, 2024 | 42.84 Mn |
| Dec 31, 2023 | 50.54 Mn |
| Sep 30, 2023 | 54.71 Mn |
| Jun 30, 2023 | 49.67 Mn |
| Mar 31, 2023 | 44.40 Mn |
| Dec 31, 2022 | 72.57 Mn |
| Jun 30, 2022 | 87.63 Mn |
| Dec 31, 2021 | 118.63 Mn |
| Jun 30, 2021 | 112.77 Mn |
| Dec 31, 2020 | -19.77 Mn |
| Dec 31, 2019 | 51.76 Mn |